Zytiga-话题@MedSci - 梅斯（MedSci）

#Zytiga#

5篇内容 | 1158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1466232, encodeId=f66f146623252, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, objectTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, objectType=article, longId=207001, objectId=7c4620e00147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4620e00147, replyNumber=0, likeNumber=80, createdTime=2021-02-11, rootId=0, userName=lqrandywkz, userId=82186780852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4620e00147, moduleTitle=ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c4620e00147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, objectTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, objectType=article, longId=188104, objectId=396c1881042f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=396c1881042f, replyNumber=0, likeNumber=77, createdTime=2020-02-16, rootId=0, userName=lqrandywkz, userId=82186780852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=396c1881042f, moduleTitle=Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=396c1881042f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1466230, encodeId=f85a146623001, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, objectTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, objectType=article, longId=160409, objectId=dada1604094f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dada1604094f, replyNumber=0, likeNumber=54, createdTime=2019-02-20, rootId=0, userName=lqrandywkz, userId=82186780852, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dada1604094f, moduleTitle=Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=dada1604094f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1466229, encodeId=0fef14662290e, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, objectTitle=欧盟委员会（EC）扩展了Zytiga的许可证，以治疗早期前列腺癌, objectType=article, longId=121138, objectId=f1131211386f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1131211386f, replyNumber=0, likeNumber=85, createdTime=2017-11-24, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1131211386f, moduleTitle=欧盟委员会（EC）扩展了Zytiga的许可证，以治疗早期前列腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f1131211386f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1466228, encodeId=991d1466228e2, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, objectTitle=重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, objectType=article, longId=43576, objectId=d305435e687, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d305435e687, replyNumber=0, likeNumber=79, createdTime=2014-12-06, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d305435e687, moduleTitle=重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d305435e687)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Zytiga

2020-05-29

lqrandywkz (审核中...)

前往app查看评论内容

#Zytiga#

ASCO GU 2021：ERLEADA联合ZYTIGA治疗转移性去势抵抗性前列腺癌III期临床

2021-02-11

lqrandywkz (审核中...)

前往app查看评论内容

#Zytiga#

Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

2020-02-16

lqrandywkz (审核中...)

前往app查看评论内容

#Zytiga#

Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究

2019-02-20

爆笑小医 (审核中...)

前往app查看评论内容

#Zytiga#

欧盟委员会（EC）扩展了Zytiga的许可证，以治疗早期前列腺癌

2017-11-24

爆笑小医 (审核中...)

前往app查看评论内容

#Zytiga#

重磅！强生Zytiga霸主地位不保，安斯泰来前列腺癌药物Xtandi拿下欧美2大市场

2014-12-06

科室
- - 订阅+
  - 更多科室
工具
服务